Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy21For the Studies of Ocular Complications of AIDS Research Group.22Conflict of interest: Statements on file with the SOCA Coordinating Center, The Johns Hopkins University School of Hygien... (original) (raw)

2002, American Journal of Ophthalmology

Abstract

PURPOSE: To describe the characteristics of patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy (HAART).

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (56)

  1. Joni Blais, RN; Kay Doyle, RN; Victor Fainstein, MD; Pamela Frady, COMT; Ronald Gross, MD; Eric Holz, MD; Silvia Orengo-Nania, MD; Varsha Patel, RPh; Tobias C. Samo, MD;
  2. Laura Shawver, COT; James W. Shigley, CRA;
  3. Benita Slight, COT; Steven Spencer, BA, COMT; Mary Weinert, MD. Emory University Eye Center, Atlanta, GA. Daniel F. Martin, MD (Director);
  4. John Closek, COT; David Fu- rukuwa, PA; Deborah Gibbs, COMT; James Gilman, CRA; John Jernigan, MD; Kathy Moore-Closek, OT; Bob Myles, CRA; Susan Rogers, PharmD; James P. Steinberg, MD. Indiana University, Indianapolis, IN. L. Joseph Wheat, MD (Director);
  5. Thomas Ciulla, MD; Ronald Danis, MD;
  6. Jean Decker, RN, CS; Linda Pratt, RN; Tim Steffens, CRA; Beth Zwickl, RN, CS, MSN. Johns Hopkins University School of Medicine, Baltimore, MD. J.P. Dunn, MD (Director);
  7. John Bartlett, MD; Ste- phen G. Bolton, CRNP; Diane M. Brown, RN; Lisa M. Brune, RN, BSN; Douglas A. Jabs, MD, MBA; John H. Kempen, MD, PhD, Jennifer E. Thorne, MD; Laura G. Neisser, COT. Former members: Susan LaSalvia, RN;
  8. Rebecca Becker, PA-C; Paul A. Latkany, MD. Louisiana State University Medical Center, New Orleans, LA. Bruce Barron, MD (Director); John Bennett; Robin Bye, RN; Rebecca Clark, MD; Mandi Conway, MD; Robin Cooper, COT; Larry Dillon, COT; Christine Jarrott, RN;
  9. Gholam Peyman, MD; Christine Romero, COT; Alina Stringer, RN; James Zachary, MD. New York Hospital-Cornell Medical Center, New York, NY. Murk-Hein Heinemann, MD (Director); Kenneth Boyd; Diane Iglesias; Roberta Janis, RN, BSN; Jean Ma- makos, RN, MSN; Firas M. Rahhal, MD; Kent Sepkowitz, MD; General Clinical Research Center, New York Hospi- tal-Cornell Medical Center. New Jersey Medical School, Newark, NJ. Ronald Rescigno, MD (Director);
  10. Patricia Kloser, MD; Rosa Paez- Boham, COST; Christopher Seery, MD; Marsha Stern, CO-COT. New York University Medical Center, New York, NY.
  11. Dorothy N. Friedberg, PhD (Director);
  12. Adrienne Addessi, MA, RN; Abraham Chachoua, MD; Douglas Dieterich, MD; Jason Hill; Richard Hutt, RN; Jonathan Ligh, MD;
  13. Monica Lorenzo-Latkany, MD; Maria Pei; Therese Powers, MS; Carol Scoppe. Northwestern University, Chicago, IL. David V. Wein- berg, MD (Director);
  14. Lee M. Jampol, MD; Alice T. Lyon, MD;
  15. Annmarie Mun ˜ana, RN; Robert L. Murphy, MD;
  16. Frank Palella, MD; Len Richine; Zuzanna Strugala, OMA; Gloria Valadez. University of California, Irvine, CA. Baruch D. Kupper- mann, MD, PhD (Director);
  17. Marcia Alcouloumre, MD;
  18. Donald N. Forthal, MD; Jeff Grijalva, COT; Karen Lopez; Nader Moinfar, MD; Mark Thomas, CRA; Randy Wil- liams. REFERENCES
  19. Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc 1995;93:623-683.
  20. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus dis- ease treated with zidovudine. The Zidofudine Epidemiology Study Group. J Infect Dis 1992;166:1223-1227.
  21. Pertel P, Hirschtick RE, Phair J, Chmiel JS, Poggensee L, Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquired Immune Defic Syndr 1992;5:1069 -1074.
  22. Hoover DR, Peng Y, Saah A, et al. Occurrence of cytomeg- alovirus retinitis after human immunodeficiency virus immu- nosuppression. Arch Ophthalmol 1996;114:821-827.
  23. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
  24. Komanduri KV, Viswanathan MN, Wieder ED, et al. Resto- ration of cytomegalovirus-specific CD4 ϩ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nature Med 1998;4:953-995.
  25. Jabs DA, Bartlett JG. AIDS and ophthalmology: A period of transition. Am J Ophthalmol 1997;124:227-233.
  26. Holtzer CD, Jacobson MA, Hadley WK, et al. Decline in the rate of specific opportunistic infections at San Francisco General Hospital. AIDS 1998;12:1931-1993.
  27. Jacobson MA, Stanley H, Holtzer C, Margolis TP, Cunning- ham ET. Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30:231- 233.
  28. Jabs DA, Bolton G, Dunn JP, Palestine AG. Discontinuing anti-CMV therapy in patients with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmol 1998;126:817-822.
  29. Tural C, Romeu J, Sirera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998;177:1080 -1083.
  30. Macdonald JC, Torriani FJ, Morse LS, Karavellas MP, Reed JB, Freeman WR. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T-cells in response to highly active antiretroviral therapy. J Infect Dis 1998;177:1182-7.
  31. Whitcup SM, Fortin E, Lindblad S, et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA 1999;282: 1633-1637.
  32. Torriani FJ, Freeman WR, Macdonald JC, et al. CMV retinitis recurs after stopping treatment in virological and immunological failure of potent antiretroviral therapy. AIDS 2000;14:173-180.
  33. Zegans ME, Walton RC, Holland GN, O'Donnell JJ, Jacob- son MA, Margolis TP. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1998;125:292-300.
  34. Karavellas MP, Lowder CY, Macdonald JC, Avila CP, Freeman WR. Immune recovery vitritis associated with inactive CMV retinitis: A new syndrome. Arch Ophthalmol 1998;6:169 -175.
  35. Karavellas MP, Plummer DJ, Macdonald JC, et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis 1999;179:697-700.
  36. Nguyen QD, Kempen JH, Bolton SG, Dunn JP, Jabs DA. Immune recovery uveitis in patients with AIDS and cyto- megalovirus retinitis following highly active antiretroviral therapy. Am J Ophthalmol 2000;129:634 -639.
  37. Robinson MR, Reed G, Csaky KG, Polis MA, Whitcup SM. Immune-recovery uveitis in patients with cytomegalovirus retinitis taking highly active antiretroviral therapy. Am J Ophthalmol 2000;130:49 -56.
  38. Karavellas MP, Mikyoung S, Macdonald JC, Freeman WR. Long-term posterior and anterior segment complications of immune recovery uveitis associated with cytomegalovirus retinitis. Am J Ophthalmol 2000;130:57-64.
  39. Centers for Disease Control and Prevention. Revised classi- fication system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;1993:41:1-19.
  40. Ferris FL III, Kassof A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol 1982; 94:91-96.
  41. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group: Foscar- net-Ganciclovir Cytomegalovirus Retinitis Trial 1. Ratio- nale, design and methods. Controlled Clin Trials 1992;13: 22-39.
  42. Diabetic Retinopathy Study Research Group. Photocoagula- tion treatment of proliferative diabetic retinopathy: the second report of Diabetic Retinopathy Study findings. Oph- thalmology 1978;85:82-106.
  43. Studies of Ocular Complications of AIDS in collaboration with the AIDS Clinical Trials Group. Foscarnet-ganciclovir cytomegalovirus retinitis trial: 4. Visual outcomes. Ophthal- mology 1994;101:1250 -1261.
  44. Studies of Ocular Complications of AIDS in collaboration with the AIDS Clinical Trials Group. Combination foscar- net and ganciclovir therapy versus monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Arch Ophthalmol 1996;114:23-33.
  45. The Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group: MSL-109 adjuvant therapy for cytomegalovirus reti- nitis in patients with acquired immunodeficiency syndrome. The Monoclonal Antibody Cytomegalovirus Retinitis Trial. Arch Ophthalmol 1997;115:1528 -1536.
  46. The Studies of Ocular Complications of AIDS Research Group in collaboration with The AIDS Clinical Trials Group: The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with AIDS: The Ganciclovir Cidofovir Retinitis Trial. Am J Ophthalmol 2001;131:457-467.
  47. Jabs DA, Forman M, Enger C, Jackson JB, for the Cytomeg- alovirus Retinitis and Viral Resistance Study Group. Com- parison of cytomegalovirus loads in plasma and leukocytes of patients with cytomegalovirus retinitis. J Clin Microbiol 1999;37:1431-1435.
  48. Altman DG. Practical statistics for medical research. Lon- don: Chapman and Hall, 1993: pp. 179 -276.
  49. Liang KY, Zeger SL. Longitudinal data analysis using gener- alized estimating linear models. Biometrika 1986;73:13-22.
  50. Tukey JW. Exploratory data analysis. Reading: Addison- Wesley, 1977: pp. 27-56.
  51. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group: Foscar- net-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Am J Ophthalmol 1997;124:141-157.
  52. Gayle H. An overview of the global HIV/AIDS epidemic, with a focus on the United States. AIDS 2000;14 (Suppl 2):S8 -S17.
  53. Lowder CY, Butler CP, Dodds EM, Secic M, Recillas- Gispert, C. CD8 ϩ T lymphocytes and cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 1995;120:283-290.
  54. Tay-Kearney ML, Enger C, Semba RD, Royal W III, Dunn JP, Jabs DA. T-cell subsets and cytomegalovirus retinitis in immunodeficiency virus-infected patients. J Infect Dis 1997;176:790 -794.
  55. Kuppermann BD, Petty JG, Richman DD, et al. Correlation between CD4 ϩ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfec- tious retinal vasculopathy in patients with acquired immunode- ficiency syndrome. Am J Ophthalmol 1993;115:575-582.
  56. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral ther- apy. Lancet 1997;349:1443-1445.